Werewolf Therapeutics, Inc.
HOWL
$0.86
-$0.06-6.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | -- |
| Cost of Revenue | 10.86M | 973.00K | 12.32M | 12.38M | 11.64M |
| Gross Profit | -10.86M | -973.00K | -12.32M | -12.38M | -11.64M |
| SG&A Expenses | 4.86M | 5.18M | 5.68M | 7.97M | 5.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.73M | 17.54M | 17.99M | 20.35M | 17.12M |
| Operating Income | -15.73M | -17.54M | -17.99M | -20.35M | -17.12M |
| Income Before Tax | -16.37M | -17.98M | -18.09M | -20.40M | -16.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.37M | -17.98M | -18.09M | -20.40M | -16.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.37M | -17.98M | -18.09M | -20.40M | -16.67M |
| EBIT | -15.73M | -17.54M | -17.99M | -20.35M | -17.12M |
| EBITDA | -15.32M | -17.14M | -17.57M | -19.91M | -16.67M |
| EPS Basic | -0.36 | -0.40 | -0.40 | -0.46 | -0.38 |
| Normalized Basic EPS | -0.22 | -0.25 | -0.25 | -0.29 | -0.24 |
| EPS Diluted | -0.36 | -0.40 | -0.40 | -0.46 | -0.38 |
| Normalized Diluted EPS | -0.22 | -0.25 | -0.25 | -0.29 | -0.24 |
| Average Basic Shares Outstanding | 45.80M | 44.98M | 44.83M | 44.48M | 43.70M |
| Average Diluted Shares Outstanding | 45.80M | 44.98M | 44.83M | 44.48M | 43.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |